Cargando…

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease

Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease (ESRD). To evaluate the efficacy and safety of different types of mineralocorticoid receptor antagonists (MRAs) in diabetic kidney disease patients, we conducted this network meta-analysis by performing a systematic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yichuan, Lin, Huanjia, Tao, Yuan, Xu, Ying, Chen, Jiaqi, Jia, Yijie, Zheng, Zongji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523214/ https://www.ncbi.nlm.nih.gov/pubmed/36188560 http://dx.doi.org/10.3389/fphar.2022.967317

Ejemplares similares

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
por: Gou, Wen-Jun, et al.
Publicado: (2022)

Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis
por: Jiang, Xinrui, et al.
Publicado: (2022)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease
por: Zou, Meina, et al.
Publicado: (2021)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
por: Orena, Stephen, et al.
Publicado: (2013)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis
por: Zhu, Yifan, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in High‐Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease
por: Pitt, Bertram, et al.
Publicado: (2017)

Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease
por: Cooper, Lauren B., et al.
Publicado: (2017)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus
por: Wish, Jay B., et al.
Publicado: (2022)

Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis
por: Chen, Meng-Die, et al.
Publicado: (2016)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
por: Tesch, Greg H., et al.
Publicado: (2017)

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
por: Currie, Gemma, et al.
Publicado: (2016)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis
por: Takahashi, S, et al.
Publicado: (2016)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury
por: Howard, Zachary M., et al.
Publicado: (2022)

A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis
por: Korol, Sandra, et al.
Publicado: (2017)

Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses
por: Felipe, Camila Q., et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges
por: Fujii, Wataru, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
por: Chang, Wei-Ting, et al.
Publicado: (2022)

Nonsteroidal Mineralocorticoid Receptor Antagonists and Protection Against Cardiovascular Disease in Patients with Diabetes Mellitus
por: Shimabukuro, Michio
Publicado: (2023)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m4n3ekg3d4o2n765ghrtivub58